Loading…
Revelation Biosciences, Inc. is projected to rise to $1.28 by 2027, a +17% move from its current price of $1.09. REVB is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $1.06 | $1.09 | $1.12 | +0.05% |
| May 30 | $1.05 | $1.09 | $1.14 | +0.09% |
| May 31 | $1.04 | $1.09 | $1.15 | +0.14% |
| Jun 1 | $1.03 | $1.09 | $1.16 | +0.19% |
| Jun 2 | $1.02 | $1.09 | $1.17 | +0.23% |
| Jun 3 | $1.02 | $1.09 | $1.18 | +0.28% |
| Jun 4 | $1.01 | $1.09 | $1.18 | +0.33% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $1.01 | $1.09 | $1.18 | +0.33% |
| Week 2 | $0.981 | $1.10 | $1.23 | +0.65% |
| Week 3 | $0.9597 | $1.10 | $1.26 | +0.98% |
| Week 4 | $0.9426 | $1.10 | $1.29 | +1.31% |
| Week 5 | $0.9282 | $1.11 | $1.32 | +1.64% |
| Week 6 | $0.9157 | $1.11 | $1.35 | +1.98% |
| Week 7 | $0.9045 | $1.12 | $1.37 | +2.31% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Revelation Biosciences, Inc. operates as a clinical-stage life science company that focuses on the rebalancing inflammation to optimize health. The company’s lead product candidate is Gemini, a proprietary formulation platform of phosphorylated hexaacyl disaccharide (PHAD), an established Toll-like receptor 4 (TLR) agonist that works by modulating and rebalancing a dysregulated inflammatory response.
It also engages in the prevention and treatment of disease by developing and commercializing therapeutics that modulate the innate immune system, including GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.
The company was formerly known as Petra Acquisition, Inc. and changed its name to Revelation Biosciences, Inc. in January 2022. Revelation Biosciences, Inc. was incorporated in 2019 and is based in San Diego, California.
REVB is the Revelation Biosciences, Inc. equity with current price $1.07 and market capitalization $4.18M. It is ranked 5387 by market capitalization. The stock’s price and market metrics place it among micro-cap to small-cap peers in the healthcare space.
The price outlook shown in the provided forecast spans from 2026 through 2050, with the average price gradually rising over time from the mid-$1 range to higher levels later in the period. The long-range forecast highlights notable upside in the 2030s and beyond, culminating in an average price of $3.65 by 2050.
Overall, the forecast depicts a path of potential growth with rising averages and sizable upside in later years, though early years are described with neutral sentiment and modest gains. These figures are estimates and not guarantees of future results.
A major floor 26.3% below — a decisive break under it would weaken the trend.
The nearest floor, 11.9% below — buyers have tended to step in here.
The nearest ceiling, 15.6% above — a clean break opens room to run.
A major ceiling 248.3% above — clearing it would confirm fresh momentum.
Key REVB support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of REVB market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $1.08 | Buy | $1.07 | Buy |
| MA 10 | $1.05 | Buy | $1.06 | Buy |
| MA 20 | $1.05 | Buy | $1.07 | Buy |
| MA 50 | $1.13 | Sell | $1.23 | Sell |
| MA 100 | $1.61 | Sell | $2.24 | Sell |
| MA 200 | $3.81 | Sell | $79.36 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.04 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 59.94 | Neutral |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.01 | Buy |
| ROC (12) | 13.54 | Buy |
| Bollinger %B (20,2) | 0.68 | Neutral |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | -0.48 | Sell |
| Awesome (5,34) | -0.03 | Sell |
| Ultimate (7,14,28) | 67.84 | Neutral |
| Momentum (10) | 0.05 | Buy |
| Aroon Osc (25) | -40.00 | Sell |
| Hull MA (9) | 1.09 | Buy |
| ADX (14) | 18.56 | Neutral |
| ATR (14) | 0.03 | Info |
The 30-day technical picture shows neutral sentiment with an RSI of 50. The 50-day simple moving average sits at $1.14, while the 200-day simple moving average is much higher at $3.90, suggesting a long-term downtrend relative to the near-term price.
Key support is at $0.96 and resistance at $1.26, framing a modest near-term trading range. The 30-day range spans from $0.8739 to $1.31, indicating relative price stability within a narrow band over the last month. Given the swing between support and resistance, traders may look for a breakout above $1.26 or a test of the $0.96 level for potential directional moves.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.96 | $1.09 | $1.64 | 0% | Neutral | |
| $1.01 | $1.28 | $1.73 | +17% | Neutral | |
| $1.03 | $1.36 | $1.91 | +25% | Bullish | |
| $0.9999 | $1.34 | $1.95 | +23% | Bullish | |
| $0.9012 | $1.24 | $1.84 | +14% | Neutral | |
| $0.9293 | $1.30 | $1.98 | +20% | Neutral | |
| $0.8857 | $1.27 | $1.97 | +16% | Neutral | |
| $1.01 | $1.47 | $2.32 | +35% | Bullish | |
| $1.21 | $1.80 | $2.89 | +65% | Bullish | |
| $1.12 | $1.69 | $2.75 | +55% | Bullish | |
| $1.26 | $2.05 | $3.58 | +88% | Bullish | |
| $2.01 | $3.72 | $7.13 | +241% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.96 | $1.09 | $1.28 | +0.00% |
| June 2026 | $0.9156 | $1.08 | $1.30 | -1.15% |
| July 2026 | $0.9575 | $1.14 | $1.39 | +5.55% |
| August 2026 | $0.9805 | $1.17 | $1.45 | +3.14% |
| September 2026 | $0.9745 | $1.17 | $1.47 | -0.02% |
| October 2026 | $1.01 | $1.22 | $1.54 | +4.34% |
| November 2026 | $1.06 | $1.29 | $1.64 | +5.34% |
| December 2026 | $1.05 | $1.28 | $1.64 | -0.43% |
Click any year to see its month-by-month REVB forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The REVB price prediction for 2026 points to an average of $1.09 (low $0.96, high $1.64) — a potential gain of 0% on today's $1.09. Price action looks broadly range-bound.
In 2027, REVB is projected to trade between $1.01 and $1.73, averaging $1.28 — a potential gain of +17% from today's $1.09. That is up +17% on the projected 2026 average. A consolidation phase looks the most probable path here.
Revelation Biosciences, Inc.'s 2028 outlook centres on $1.36, within a $1.03 to $1.91 range. That is up +6% on the projected 2027 average. That marks a +25% change versus current levels. Momentum favours further upside here.
By 2029, REVB could reach as high as $1.95, with a base case around $1.34 and support toward $0.9999 — roughly +23% from $1.09. Buyers look set to stay in control over this stretch.
Expect REVB to range from $0.9012 to $1.84 through 2030. The $1.24 average target implies a +14% move from current prices. That is -8% versus the projected 2029 average. Price action looks broadly range-bound.
The REVB price prediction for 2031 points to an average of $1.30 (low $0.9293, high $1.98) — a potential gain of +20% on today's $1.09. A consolidation phase looks the most probable path here.
In 2032, REVB is projected to trade between $0.8857 and $1.97, averaging $1.27 — a potential gain of +16% from today's $1.09. That is -3% versus the projected 2031 average. Price action looks broadly range-bound.
Revelation Biosciences, Inc.'s 2033 outlook centres on $1.47, within a $1.01 to $2.32 range. That is up +16% on the projected 2032 average. That marks a +35% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, REVB could reach as high as $2.89, with a base case around $1.80 and support toward $1.21 — roughly +65% from $1.09. Momentum favours further upside here.
Expect REVB to range from $1.12 to $2.75 through 2035. The $1.69 average target implies a +55% move from current prices. That is -6% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The REVB price prediction for 2040 points to an average of $2.05 (low $1.26, high $3.58) — a potential gain of +88% on today's $1.09. Momentum favours further upside here.
In 2050, REVB is projected to trade between $2.01 and $7.13, averaging $3.72 — a potential gain of +241% from today's $1.09. That is up +81% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in REVB today (≈ 917.431193 REVB) could be worth
$3,412.63
+$2,412.63 (+241%) by 2050 · US Dollar
Based on the average projected REVB price of $3.72 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in REVBwould be worth at today's price.
$1,000 invested in REVB on May 27, 2025 (≈ 36.71072 REVB) would be worth
$40.01
-$959.99 (-96.0%) today · 0.04× · US Dollar
Based on a REVB entry price of $27.24 vs. today's $1.09.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $1.09 | $1,000 | -0.0% |
| 1 month ago | $1.15 | $947.83 | -5.2% |
| 3 months ago | $1.33 | $819.55 | -18.0% |
| 6 months ago | $3.82 | $285.34 | -71.5% |
| 1 year ago | $27.24 | $40.01 | -96.0% |
| All time (5.0y) ago | $2,020,032 | $0 | -100.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our REVB forecast.
Our base-case forecast reaches $2.20 around 2050.
Implied market cap at $2.20: $8.6M
The multi-year forecast shows a stepwise path with an early neutral stance and later bullish periods. In 2026 the avg price is $1.07 with a 0 ROI and NEUTRAL sentiment. By 2027 the avg is $1.26 with an 18.2 ROI and NEUTRAL sentiment, and 2028 features an avg of $1.34 with a 25.2 ROI and BULLISH sentiment.
In 2029 the avg is $1.32 with a 23.4 ROI and BULLISH sentiment, and 2030 follows at an avg of $1.22 with a 14.1 ROI and NEUTRAL sentiment. The 2031 and 2032 forecasts show 2031 avg $1.28 (19.7 ROI, NEUTRAL) and 2032 avg $1.24 (15.9 ROI, NEUTRAL).
From 2033 onward, sentiment turns BULLISH, with 2033 avg $1.45 (35.9 ROI), 2034 avg $1.78 (66.1 ROI), and 2035 avg $1.65 (54.1 ROI).
The long-range view strengthens into 2040 with an avg of $2.03 and 90 ROI in a BULLISH period, and culminates in 2050 with an avg of $3.65 and 240.7 ROI, also labeled BULLISH. These are estimates and not guarantees of future performance.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $1.22 with a 14.1 ROI and NEUTRAL sentiment. The min and max for 2030 are $0.8826 and $1.83 respectively. These figures are estimates, not guarantees.
Forecasts indicate neutrality through 2032, with bullish sentiment emerging in 2033 and continuing through 2050. The 2033–2050 periods show rising averages and higher ROIs, including a 35.9 ROI in 2033, 66.1 ROI in 2034, and 240.7 ROI in 2050, suggesting potential upside but with uncertainty and no guarantees.
According to the forecast, the 2040 average price is $2.03 and the 2050 average price is $3.65, indicating the potential to surpass $2 by 2040. The 2034–2035 period also shows bullish momentum with higher averages, but these are not guaranteed.
Current price: $1.07. Market cap: $4.18M. These figures reflect the present market position as provided.
The 30-day range is from a low of $0.8739 to a high of $1.31, indicating the near-term trading span within that window.
Revelation Biosciences, Inc. Community Discussion
0Share your Revelation Biosciences, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.